936P Analysis of different EGFR mutations affecting the efficacy of postoperative adjuvant therapy for resectable non-small cell lung cancer

Abstract

The ADAURA study opens the door for precision medicine and biomarker testing to enter the early stage of non-small cell lung cancer (NSCLC), that is, the precise decision-making of postoperative adjuvant therapy for early-stage. As previously reported, NSCLC patients with different EGFR mutants display heterogeneous clinical course and their different response to EGFR-TKIs, but weather their responses to adjuvant chemotherapy are various is still unclear.